Cargando…

Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer

SIMPLE SUMMARY: Pancreatic cancer is one of the most heterogeneous and aggressive tumours that exist. The median survival of diagnosed patients is limited. For all these reasons, it is necessary to develop new disease markers that allow guidelines for clinical action to improve the average survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Pekarek, Leonel, Fraile-Martinez, Oscar, Garcia-Montero, Cielo, Saez, Miguel A., Barquero-Pozanco, Ines, del Hierro-Marlasca, Laura, de Castro Martinez, Patricia, Romero-Bazán, Adoración, Alvarez-Mon, Miguel A., Monserrat, Jorge, García-Honduvilla, Natalio, Buján, Julia, Alvarez-Mon, Melchor, Guijarro, Luis G., Ortega, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029823/
https://www.ncbi.nlm.nih.gov/pubmed/35454771
http://dx.doi.org/10.3390/cancers14081866
_version_ 1784691994144014336
author Pekarek, Leonel
Fraile-Martinez, Oscar
Garcia-Montero, Cielo
Saez, Miguel A.
Barquero-Pozanco, Ines
del Hierro-Marlasca, Laura
de Castro Martinez, Patricia
Romero-Bazán, Adoración
Alvarez-Mon, Miguel A.
Monserrat, Jorge
García-Honduvilla, Natalio
Buján, Julia
Alvarez-Mon, Melchor
Guijarro, Luis G.
Ortega, Miguel A.
author_facet Pekarek, Leonel
Fraile-Martinez, Oscar
Garcia-Montero, Cielo
Saez, Miguel A.
Barquero-Pozanco, Ines
del Hierro-Marlasca, Laura
de Castro Martinez, Patricia
Romero-Bazán, Adoración
Alvarez-Mon, Miguel A.
Monserrat, Jorge
García-Honduvilla, Natalio
Buján, Julia
Alvarez-Mon, Melchor
Guijarro, Luis G.
Ortega, Miguel A.
author_sort Pekarek, Leonel
collection PubMed
description SIMPLE SUMMARY: Pancreatic cancer is one of the most heterogeneous and aggressive tumours that exist. The median survival of diagnosed patients is limited. For all these reasons, it is necessary to develop new disease markers that allow guidelines for clinical action to improve the average survival of patients with pancreatic cancer. ABSTRACT: The incidence and prevalence of pancreatic adenocarcinoma have increased in recent years. Pancreatic cancer is the seventh leading cause of cancer death, but it is projected to become the second leading cause of cancer-related mortality by 2040. Most patients are diagnosed in an advanced stage of the disease, with very limited 5-year survival. The discovery of different tissue markers has elucidated the underlying pathophysiology of pancreatic adenocarcinoma and allowed stratification of patient risk at different stages and assessment of tumour recurrence. Due to the invasive capacity of this tumour and the absence of screening markers, new immunohistochemical and serological markers may be used as prognostic markers for recurrence and in the study of possible new therapeutic targets because the survival of these patients is low in most cases. The present article reviews the currently used main histopathological and serological markers and discusses the main characteristics of markers under development.
format Online
Article
Text
id pubmed-9029823
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90298232022-04-23 Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer Pekarek, Leonel Fraile-Martinez, Oscar Garcia-Montero, Cielo Saez, Miguel A. Barquero-Pozanco, Ines del Hierro-Marlasca, Laura de Castro Martinez, Patricia Romero-Bazán, Adoración Alvarez-Mon, Miguel A. Monserrat, Jorge García-Honduvilla, Natalio Buján, Julia Alvarez-Mon, Melchor Guijarro, Luis G. Ortega, Miguel A. Cancers (Basel) Review SIMPLE SUMMARY: Pancreatic cancer is one of the most heterogeneous and aggressive tumours that exist. The median survival of diagnosed patients is limited. For all these reasons, it is necessary to develop new disease markers that allow guidelines for clinical action to improve the average survival of patients with pancreatic cancer. ABSTRACT: The incidence and prevalence of pancreatic adenocarcinoma have increased in recent years. Pancreatic cancer is the seventh leading cause of cancer death, but it is projected to become the second leading cause of cancer-related mortality by 2040. Most patients are diagnosed in an advanced stage of the disease, with very limited 5-year survival. The discovery of different tissue markers has elucidated the underlying pathophysiology of pancreatic adenocarcinoma and allowed stratification of patient risk at different stages and assessment of tumour recurrence. Due to the invasive capacity of this tumour and the absence of screening markers, new immunohistochemical and serological markers may be used as prognostic markers for recurrence and in the study of possible new therapeutic targets because the survival of these patients is low in most cases. The present article reviews the currently used main histopathological and serological markers and discusses the main characteristics of markers under development. MDPI 2022-04-07 /pmc/articles/PMC9029823/ /pubmed/35454771 http://dx.doi.org/10.3390/cancers14081866 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pekarek, Leonel
Fraile-Martinez, Oscar
Garcia-Montero, Cielo
Saez, Miguel A.
Barquero-Pozanco, Ines
del Hierro-Marlasca, Laura
de Castro Martinez, Patricia
Romero-Bazán, Adoración
Alvarez-Mon, Miguel A.
Monserrat, Jorge
García-Honduvilla, Natalio
Buján, Julia
Alvarez-Mon, Melchor
Guijarro, Luis G.
Ortega, Miguel A.
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
title Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
title_full Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
title_fullStr Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
title_full_unstemmed Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
title_short Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
title_sort clinical applications of classical and novel biological markers of pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029823/
https://www.ncbi.nlm.nih.gov/pubmed/35454771
http://dx.doi.org/10.3390/cancers14081866
work_keys_str_mv AT pekarekleonel clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT frailemartinezoscar clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT garciamonterocielo clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT saezmiguela clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT barqueropozancoines clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT delhierromarlascalaura clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT decastromartinezpatricia clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT romerobazanadoracion clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT alvarezmonmiguela clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT monserratjorge clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT garciahonduvillanatalio clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT bujanjulia clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT alvarezmonmelchor clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT guijarroluisg clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer
AT ortegamiguela clinicalapplicationsofclassicalandnovelbiologicalmarkersofpancreaticcancer